Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.35 |
| ▸ | ERN1 | O75460 | 3/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10079569 | 0.79 | CYP11B2 (0.38) | CYP11B2KCNQ2ADRA1DADRA1AADRA1B | |
| SCHEMBL6508612 | 0.77 | LMNA (0.37) | — | |
| SCHEMBL29212964 | 0.74 | ERN1 (0.36) | CYP11B2ERN1CYP11B1CYP3A4 | |
| SCHEMBL21736827 | 0.71 | CYP11B2 (0.36) | CYP11B2KCNQ2ADRA1DADRA1AADRA1B | |
| SCHEMBL31489084 | 0.71 | ERN1 (0.37) | ERN1 | |
| SCHEMBL24105759 | 0.71 | ERN1 (0.52) | ERN1 | |
| SCHEMBL7184430 | 0.71 | ERN1 (0.52) | ERN1 | |
| SCHEMBL30116842 | 0.71 | ERN1 (0.52) | ERN1 | |
| SCHEMBL6118780 | 0.69 | ERN1 (0.36) | ERN1 | |
| SCHEMBL21736891 | 0.69 | CYP11B2 (0.40) | CYP11B2KCNQ2ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051345-A1 | PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2025-02-13 | — | — | US | disclosed |
| EP-4448533-A1 | <SUP2/>? <SUB2/>?V?PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CA1.2 ACTIVATORS | Novartis AG (CH) | 2024-10-23 | — | — | EP | disclosed |
| CN-118510782-A | As CaV1.2 Pyridine-3-carboxylic acid ester Compounds of activators | 诺华股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023111799-A1 | PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CaV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2023-06-22 | — | — | WO | disclosed |
| EP-2757883-B1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2757883-B1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| US-9567333-B2 | Triazolopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567333-B2 | Triazolopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567333-B2 | Triazolopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160039817-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160039817-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160039817-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2016-02-11 | — | — | US | disclosed |
| US-9193724-B2 | Triazolopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193724-B2 | Triazolopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193724-B2 | Triazolopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140228396-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140228396-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140228396-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| WO-2013043520-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039817-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, HSD11B1, CYP17A1 | CYP11B2 4/4885ERN1 800/4885KCNQ2 1214/4885 |
| US-20140228396-A1 | TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP17A1, CYP11B2 | CYP11B2 3/4885ERN1 770/4885KCNQ2 1180/4885 |
| US-20250051345-A1 | PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | CACNA1D, CACNA1S, CACNA1I | CYP11B2 1195/4885ERN1 4742/4885KCNQ2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.